Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | methotrexate | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, Cell transfection, Western blot etc. |
| Sample | cell lines (HT-29 and HT-29 resistant cell) |
| Expression Pattern | up-regulated |
| Function Description | LncRNA H19 was found to be significantly upregulated in this resistant cell line. Further investigation showed that H19 knockdown sensitized the MTX resistance in HT-29-R cells while its overexpression improved the MTX resistance in the parental cells, suggesting that H19 mediate MTX resistance. The Wnt/B-catenin signaling was activated in HT-29-R cells, and H19 knockdown suppressed this signaling in the parental cells. |
| Pubmed ID | 27919747 |
| Year | 2017 |
| Title | H19 mediates methotrexate resistance in colorectal cancer through activating Wnt/B-catenin pathway. |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |